Evidence map›Paper›PMID 37182840›Full record

ArticleLaboratory investigation; a journal of technical methods and pathology2023

Using Artificial Intelligence to Identify Tumor Microenvironment Heterogeneity in Non-Small Cell Lung Cancers.

Tanner J DuCote, Kassandra J Naughton, Erika M Skaggs, Therese J Bocklage, Derek B Allison, Christine F Brainson

Open access · bronzeAbstract read
In one paragraph

Article in Laboratory investigation; a journal of technical methods and pathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Artificial intelligence-enabled histological analysis in pre-clinical respiratory disease models: a scoping review.European respiratory review : an official journal of the European Respiratory Society · 2026
    Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Tanner J DuCoteDepartment of Toxicology and Cancer Biology, University of Kentucky, Lexington, Kentucky.
Kassandra J NaughtonDepartment of Toxicology and Cancer Biology, University of Kentucky, Lexington, Kentucky.
Erika M SkaggsDepartment of Toxicology and Cancer Biology, University of Kentucky, Lexington, Kentucky.
Therese J BocklageMarkey Cancer Center, University of Kentucky, Lexington, Kentucky; Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, Kentucky.
Derek B AllisonMarkey Cancer Center, University of Kentucky, Lexington, Kentucky; Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, Kentucky.
Christine F BrainsonDepartment of Toxicology and Cancer Biology, University of Kentucky, Lexington, Kentucky; Markey Cancer Center, University of Kentucky, Lexington, Kentucky. Electronic address: cfbrainson@uky.edu.
University of Kentucky · US

Funding

University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Bernard Mark Evers · 2013 to 2026
$38.3M
University of Kentucky Center for Cancer MetabolismP20GM121327 · NIGMS · UNIVERSITY OF KENTUCKY · PI Jianhang Jia · 2017 to 2026
$25.0M
Oncology Research Training for Surgeon-ScientistsT32CA160003 · NCI · UNIVERSITY OF KENTUCKY · PI Bernard Mark Evers, Pamela Carmen Hull · 2011 to 2026
$3.2M
Targeting Epigenetic Heterogeneity to Improve Lung Cancer Immunotherapy ResponseR01CA237643 · NCI · UNIVERSITY OF KENTUCKY · PI BRAINSON, CHRISTINE FILLMORE · 2019 to 2023
$1.9M
NCI NIH HHS P30 CA177558NCI NIH HHS R01 CA237643NCI NIH HHS T32 CA160003NIGMS NIH HHS P20 GM121327
6 · The paper itself

Abstract

Lung cancer heterogeneity is a major barrier to effective treatments and encompasses not only the malignant epithelial cell phenotypes and genetics but also the diverse tumor-associated cell types. Current techniques used to investigate the tumor microenvironment can be time-consuming, expensive, complicated to interpret, and often involves destruction of the sample. Here we use standard hematoxylin and eosin-stained tumor sections and the HALO AI nuclear phenotyping software to characterize 6 distinct cell types (epithelial, mesenchymal, macrophage, neutrophil, lymphocyte, and plasma cells) in both murine lung cancer models and human lung cancer samples. CD3 immunohistochemistry and lymph node sections were used to validate lymphocyte calls, while F4/80 immunohistochemistry was used for macrophage validation. Consistent with numerous prior studies, we demonstrated that macrophages predominate the adenocarcinomas, whereas neutrophils predominate the squamous cell carcinomas in murine samples. In human samples, we showed a strong negative correlation between neutrophils and lymphocytes as well as between mesenchymal cells and lymphocytes and that higher percentages of mesenchymal cells correlate with poor prognosis. Taken together, we demonstrate the utility of this AI software to identify, quantify, and compare distributions of cell types on standard hematoxylin and eosin-stained slides. Given the simplicity and cost-effectiveness of this technique, it may be widely beneficial for researchers designing new therapies and clinicians working to select favorable treatments for their patients.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAnimalsArtificial IntelligenceEosine Yellowish-(YS)HematoxylinHumansMiceTumor MicroenvironmentEosine Yellowish-(YS)Hematoxylinartificial intelligencenon–small cell lung cancertumor immunologytumor microenvironment

Identifiers

PMID37182840
PMCPMC10527157
OpenAlexW4376272655

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.